Northern Trust Corp Grows Stock Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Northern Trust Corp raised its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 5.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 613,170 shares of the company's stock after buying an additional 29,808 shares during the quarter. Northern Trust Corp owned about 1.28% of Amphastar Pharmaceuticals worth $22,767,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of AMPH. Smartleaf Asset Management LLC grew its position in Amphastar Pharmaceuticals by 222.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock valued at $26,000 after acquiring an additional 493 shares in the last quarter. Parkside Financial Bank & Trust grew its holdings in shares of Amphastar Pharmaceuticals by 806.5% in the fourth quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock valued at $36,000 after purchasing an additional 871 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in Amphastar Pharmaceuticals by 43.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock worth $43,000 after buying an additional 348 shares during the period. Huntington National Bank lifted its holdings in Amphastar Pharmaceuticals by 36.9% during the 4th quarter. Huntington National Bank now owns 1,340 shares of the company's stock worth $50,000 after buying an additional 361 shares in the last quarter. Finally, TD Private Client Wealth LLC boosted its position in Amphastar Pharmaceuticals by 22.7% in the 4th quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company's stock valued at $78,000 after buying an additional 388 shares during the period. Hedge funds and other institutional investors own 65.09% of the company's stock.

Insider Buying and Selling

In other news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the sale, the chief financial officer now owns 97,363 shares in the company, valued at approximately $2,681,377.02. The trade was a 4.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 5,231 shares of company stock worth $142,752 in the last ninety days. 27.50% of the stock is owned by corporate insiders.

Amphastar Pharmaceuticals Stock Up 2.2%

AMPH stock traded up $0.54 during midday trading on Friday, reaching $24.86. 510,253 shares of the company were exchanged, compared to its average volume of 477,103. The stock's 50-day simple moving average is $25.48 and its 200 day simple moving average is $34.14. Amphastar Pharmaceuticals, Inc. has a 1-year low of $22.64 and a 1-year high of $53.96. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The company has a market cap of $1.18 billion, a price-to-earnings ratio of 8.29, a price-to-earnings-growth ratio of 2.19 and a beta of 0.78.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Piper Sandler decreased their target price on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a report on Friday, March 21st. Wells Fargo & Company reduced their price target on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research report on Thursday, May 8th. JPMorgan Chase & Co. reissued a "neutral" rating and set a $30.00 price objective (down from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, Amphastar Pharmaceuticals presently has a consensus rating of "Hold" and a consensus price target of $32.33.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.